Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBIT Margin (2019 - 2025)

Historic EBIT Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 120.3%.

  • BridgeBio Pharma's EBIT Margin rose 68983700.0% to 120.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 172.39%, marking a year-over-year increase of 775900.0%. This contributed to the annual value of 267.22% for FY2024, which is 62615300.0% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's EBIT Margin is 120.3%, which was up 68983700.0% from 121.45% recorded in Q2 2025.
  • BridgeBio Pharma's EBIT Margin's 5-year high stood at 19953.49% during Q4 2021, with a 5-year trough of 38200.0% in Q3 2022.
  • Moreover, its 5-year median value for EBIT Margin was 6377.94% (2021), whereas its average is 6756.95%.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's EBIT Margin was 1244526700bps (2021), while the steepest drop was -388120600bps (2021).
  • BridgeBio Pharma's EBIT Margin (Quarter) stood at 19953.49% in 2021, then tumbled by -135bps to 6910.8% in 2022, then tumbled by -47bps to 10167.11% in 2023, then skyrocketed by 62bps to 3842.69% in 2024, then skyrocketed by 97bps to 120.3% in 2025.
  • Its EBIT Margin was 120.3% in Q3 2025, compared to 121.45% in Q2 2025 and 89.49% in Q1 2025.